DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Special Use - Results Surveillance on Long-term Use With Wegovy®

Conditions: Obesity

Interventions: Drug: Semaglutide

First Posted Date: 2024-02-28

Last Posted Date: 2025-05-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1000

Registration Number: NCT06283667

Locations: 🇯🇵
Japanese Red Cross Hamamatsu Hospital_Cardiology, Shizuoka, Japan
🇯🇵
Osaki citizen hospital, Diabetes and metabolic disease, Osaki-shi, Miyagi, Japan
🇯🇵
The Jikei University Hospital Dept of Diabetes, Metabolic, Tokyo, Japan

and more 70 locations

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Oral Semaglutide

First Posted Date: 2024-02-21

Last Posted Date: 2025-03-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 470

Registration Number: NCT06269120

Locations: 🇭🇺
Siklósi Kórház, Diabetológia, Siklós, Hungary

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: IcoSema
Drug: Insulin glargine

First Posted Date: 2024-02-21

Last Posted Date: 2025-04-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 474

Registration Number: NCT06269107

Locations: 🇺🇸
Methodist Phys. Clinic, Omaha, Nebraska, United States
🇺🇸
Albuquerque Clin Trials, Inc., Albuquerque, New Mexico, United States
🇺🇸
Albany Medical College - Endo, Albany, New York, United States

and more 86 locations

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Phase 1

Active, not recruiting

Conditions: Overweight
Obesity

Interventions: Other: No treatment given
Drug: Cagrilintide and Semaglutide
Drug: Placebo

First Posted Date: 2024-02-20

Last Posted Date: 2024-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 150

Registration Number: NCT06267092

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Phase 2

Recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions: Drug: NNC6019-0001

First Posted Date: 2024-02-15

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 80

Registration Number: NCT06260709

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Cedars-Sinai Medical Center_Los Angeles, Los Angeles, California, United States
🇺🇸
Stanford Hlth Cre-Boswell Clin, Stanford, California, United States

and more 29 locations

Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender

Completed

Conditions: Overweight
Obesity

Interventions: Other: No treatment is given

First Posted Date: 2024-02-15

Last Posted Date: 2024-02-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3000

Registration Number: NCT06260696

Locations: 🇦🇪
Novo Nordisk Investigational Site, Dubai, United Arab Emirates

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Cagrilintide
Drug: Tirzepatide
Drug: Semaglutide

First Posted Date: 2024-01-24

Last Posted Date: 2025-04-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1000

Registration Number: NCT06221969

Locations: 🇺🇸
South Broward Research LLC, Miramar, Florida, United States
🇺🇸
West Orange Endocrinology, Ocoee, Florida, United States
🇺🇸
Optimal Research Sites, Orange City, Florida, United States

and more 172 locations

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Cagrilintide
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2024-01-17

Last Posted Date: 2025-01-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 62

Registration Number: NCT06207877

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Phase 3

Recruiting

Conditions: Heart Failure
Systemic Inflammation

Interventions: Drug: Placebo
Drug: Ziltivekimab

First Posted Date: 2024-01-10

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 680

Registration Number: NCT06200207

Locations: 🇲🇾
Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia
🇧🇬
MHAT Heart and Brain, Pleven, Bulgaria
🇧🇬
"UMHAT "Sveti Georgi" EAD, Plovdiv, Bulgaria

and more 194 locations

A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.

Phase 1

Completed

Conditions: Healthy Volunteers (Non-alcoholic Steatohepatitis)

Interventions: Drug: NNC0194-0499
Drug: ethinylestradiol/levonorgestrel

First Posted Date: 2024-01-03

Last Posted Date: 2025-02-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT06188026

Locations: 🇦🇹
Medical University of Graz, Graz, Austria

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy